Printer Friendly

Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology.

In recent years, serum troponins have been increasingly used in the diagnosis of acute coronary syndromes as studies have shown their greater clinical sensitivity over creatine kinase-MB (CK-MB) [4] (1, 2). In patients with non-Q-wave myocardial infarction (MI) or unstable angina, serum troponins can provide risk stratification for short-term (3-9) and long-term (9,10) cardiac events and mortality. This has been attributed mainly to the ability of serum troponins to detect microinfarcts, areas of necrosis too small to produce electrocardiographic changes or increased serum cardiac enzymes. Whereas increased short-term complications and mortality may understandably be explained by these microinfarcts, long-term events have also been attributed to complications of ischemia.

Additionally, a high percentage of end-stage renal failure patients show increased cardiac troponin T (cTnT) in the absence of acute cardiac ischemia (11,12). There have been suggestions that these represent spurious increases arising from re-expression of the cardiac isoform, the fetal form, in skeletal muscles of these patients (13). We have observed a threefold increase in 1-year mortality in 172 hemodialysis patients with increased cTnT (14), and although increases in cTnT may result from silent MIs that occur frequently in these patients, the temporal pattern of increases was not in keeping with acute ischemic events. This raised the possibility that increased cTnT in this group of patients was indicative of chronic disease processes that compromise survival.

There have been reports of similar increases in mortality associated with increased cTnT in congestive heart failure (CHF) patients (15-17) and in patients with sepsis (18). These findings led us to reexamine the basis of increased troponins, especially cTnT, within the context of subclinical myocardial pathology. We used histological examination of the heart at postmortem, which can indicate the extent and type of pathology present, to determine whether increased serum troponin concentrations can be explained by subclinical myocardial pathology.

Materials and Methods


Patients were selected from those undergoing postmortem studies at the Ottawa Hospital Civic Campus Department of Pathology and Laboratory Medicine. Patients with a clinical diagnosis of MI or patients in whom no suitable antemortem plasma samples were available were excluded from the study. A total of 78 patients were studied and included 6 from a study of chronic hemodialysis patients (14).


Samples were routine clinical samples, drawn into evacuated tubes (PST[R] or SST[R]; Becton Dickinson) and processed in the routine manner. Sixty-four percent of samples were obtained within 7 days of death; samples from three dialysis patients and one cardiac patient were obtained >6 months before death. Most of the samples (88%) were frozen at -20[degrees]C within 72 h. Twelve patients were studied retrospectively; serum markers were analyzed for clinical reasons in 6, and for a previous study on chronic hemodialysis patients in 6 (14); 11 patients had only cTnT measurements, and one had CK and cTnT.

Creatine kinase was measured on the Boehringer Mannheim /Hitachi 917, using manufacturer's reagents, CK-MB and cardiac troponin I (cTnI) were measured on the AxSYM (Abbott Laboratories), and cTnT was measured on the Elecsys 1010 (Roche Diagnostics). The second-generation cTnT assay was used; this assay has no cross-reactivity with skeletal TnT. The cutoff values used in our laboratory are as follows: CK, 215 U/L for males and 160 U/L for females; CK-MB, 10 [micro]g/L; cTnI, 2.0 [micro]g/L; and cTnT 0.1 [micro]g/L. The interassay imprecision (CV) for each assay is as follows: for CK, 2.3% at 245 U/L; for CK-MB, 12% at 20 [micro]g/L and 8.7% at 124 [micro]g/L; for cTnI, 7.0% at 3.3 [micro]g/L and 7.9% at 34.2 [micro]g/L; and for cTnT, 6.5% at 0.16 [micro]g/L and 6.0% at 1.1 [micro]g/L.


Gross and histological examinations of the heart were performed by a cardiac pathologist (J.P.V.) without knowledge of the serum marker values. Postmortem examinations were completed within 24 h of death in all patients.

Patients were classified as having recent MI if there was coagulative and contraction band necrosis <5 days old; healing MI if the infarct was >1 week old as evidenced by healed edges but without significant fibrosis; and old infarcts if there was prominent fibrosis. The other cardiac disorders seen were degenerative changes associated with CHF (myocytes characterized by clear cytoplasm and loss of myofilaments, often accompanied by pericellular fibrosis), inflammation, fibrosis, nonbacterial thrombotic endocarditis, sepsis changes, amyloid deposition, and infiltration by tumor.


Means were compared using the Analysis ToolPak of Microsoft Excel, Ver. 7. [chi square] Analysis and the Fisher's exact two-tailed test were performed. Odds ratios were calculated to determine the relationship between increased serum markers and the presence of cardiac pathology, using Epi Info, Ver. 6 (Department of Surveillance and Epidemiology, CDC) and InStat, Ver. 2.04 (GraphPad Software). Statistical significance was defined as P <0.05 unless otherwise stated. Clinical sensitivities and specificities were calculated for all cardiac pathologies and for acute MI (recent and healing). For the latter diagnosis, patients with other cardiac pathologies were considered not to have disease.


A summary of 66 patients for whom all cardiac markers were measured is shown in Table 1. A complete listing of the patient characteristics, clinical diagnoses, main cardiac histologic findings, and other significant vascular diseases is available as a supplement through the Clinical Chemistry Web site. The file can be accessed by a link from the on-line Table of Contents ( content/vol46/issue 3/). There was no myocardial pathology in 15 patients; there was old MI or ventricular fibrosis in 9, recent MI in 27 (11 microinfarcts), healing MI in 7, degenerative changes in 12, and miscellaneous pathology in 8 patients.

In the patients with no myocardial pathology, CK was increased in 3 of 15, and cTnI was just below the cutoff concentration (1.9 [micro]g/L) in 1 patient. In patients with myocardial pathology, cTnT was most frequently increased. Although increases in CK were noted without increases in the other markers, increased CK-MB was associated with increased cTnI and cTnT in all patients. Similarly, all but one patient with increased cTnI had increased cTnT. The median concentrations and the percentages of patients with increased CK-MB, cTnI, and cTnT, but not CK, were higher in patients with myocardial pathology than for those with no myocardial pathology (Table 2 and Fig. 1). However, the odds ratio for the presence of acute MI was significant for cTnI and cTnT only, and the odds ratios for the presence of CHF changes and other cardiac pathologies were significant for cTnT alone. There was no significant difference between the groups with recent and healing MIs, nor did the size of the infarct appear to have any effect; hence, they were studied together. When all cardiac pathologies were considered, the clinical sensitivities (95% confidence intervals) for CK, CK-MB, cTnI, and cTnT were 38% (25-52%), 26% (15-40%), 44% (31-59%), and 53% (41-65%), respectively. The specificity for CK was 80%, whereas the other markers showed 100% specificity. For acute MI, the specificities for CK, CK-MB, cTnI, and cTnT were 75% (59-87%), 92% (79-98%), 87% (73-96%), and 73% (57-85%), respectively. The clinical sensitivities for acute MI were 22% (9-42%), 19% (6-38%), 48% (29-68%), and 62% (44-78%), respectively. When we used only the samples collected within 6 days of death, the sensitivities changed marginally to 17% (4-41%),22% (6-48%),61% (36-83%), and 70% (46-88%), respectively, and did not increase further when we restricted samples to within 3 days of death. For acute MI, the sensitivity of cTnT was not significantly different from that of cTnI, but it was significantly different from both CK-MB and CK. For cardiac pathologies other than acute MI, the sensitivity for cTnT over cTnI did not achieve statistical significance, with an observed difference of 21% and a SE of 12%.

Patients with diabetes mellitus had significantly lower CK-MB, cTnI, and cTnT; the median values for patients without and with diabetes were 2.5 vs 1.5 [micro]g/L for CK-MB; 0.3 vs 0.2 [micro]g/L for cTnI; and 0.08 vs 0.03 [micro]g/L for cTnT. However, excluding the 11 diabetic patients from the analysis did not influence the findings. The medians for cTnI and cTnT were higher in patients with chronic renal failure than for those with normal renal function (1.6 vs 0.2 [micro]g/L for cTnI and 0.20 vs 0.05 [micro]g/L for cTnT), but the differences did not achieve statistical significance. Eliminating the 12 retrospective patients and studying only the 66 patients with results available for all markers yielded similar results.

The presence of acute myocardial ischemia was the most common cause of increased serum concentrations of CK-MB, cTnI, and cTnT, contributing to >60% of increased values. Interestingly, patients with microinfarcts were just as likely to have increased values as patients with larger infarcts.


The findings of this study confirm the increased clinical sensitivity of serum troponins over CK and CK-MB in acute coronary syndromes. Many of the patients with borderline increases in serum troponins had small MIs at postmortem. Because of the nature of this study, where a single plasma sample was used, the longer period of increased concentrations seen with serum troponins following an acute ischemic event (19,20) may have contributed to the higher percentage of increased concentrations observed.

The important finding of this study was the presence of histologic changes in the hearts of almost all of the patients with increased serum CK-MB, cTnI, and cTnT. What had been considered as spurious increases, because of a lack of symptoms and clinical signs when currently available diagnostic modalities were used, is explained by diseased cardiomyocytes. Furthermore, there appears to be a difference between patients with acute ischemia and those with other myocardial disorders. In the former, the percentage of patients with increased cTnI is very similar to that for cTnT (50% vs 63%). The slightly higher positivity for cTnT can be explained by its longer half-life, which makes it more likely that a single random sample would have increased values. In patients with other myocardial pathologies, cTnT is increased more than twice as frequently as cTnI. This may explain the discordance seen between the troponins in end-stage renal failure patients but not seen in acute coronary syndromes. To explain this discrepancy, one could hypothesize that cTnT is more likely than the other markers to leak into circulation with minor pathologic changes. Approximately 6% of cTnT is present in the cytoplasm of cardiomyocytes (21) in contrast to 3% of cTnI (22). Additionally, cTnT in serum exists mainly as free subunits, whereas cTnI exists complexed as a binary structure with troponin C, or as a ternary structure with both troponins C and T (23), indicating that cTnI is released as a larger complex. Loss of cell membrane integrity could possibly allow selective leakage of cytosolic components into the circulation, with preferential leakage of cTnT when membrane damage is minor. With increasing destruction of the membrane architecture, larger cytosolic components may be leaked into circulation, leading to increases for both troponins.

Myocytes may die from several different processes, including necrosis (oncosis) and apoptosis, and it is recognized that these processes may be interrelated (24, 25). Unlike necrosis, apoptosis proceeds through a genetically programmed series of biochemical and morphological steps designed to avoid the indiscriminate release of cytosolic contents and the ensuing inflammatory response. In apoptosis, the cell membrane remains intact, at least for some time. This would lead one to hypothesize that various myocyte cellular components appear in circulation at the different times of apoptotic and necrotic cell death.

The increased mortality seen with increased troponins, especially cTnT, in nonischemic settings supports our findings. We had been perplexed previously by the increased mortality associated with unexplained increases in cTnT in chronic hemodialysis patients (14). Two recent studies (26,27) in dialysis patients have shown similar associated mortality. In our study (14), we were surprised to find that increased cTnT is a better predictor of mortality in patients without coronary artery or peripheral vascular disease and in non-diabetics, the groups traditionally considered at lower mortality risk for atherosclerosis. This now can be explained by cTnT reflecting subclinical myocardial pathology rather than acute coronary ischemia. Furthermore, we found a higher mortality risk associated with increased cTnT in the nonhypertensive group. Whereas systemic arterial hypertension is associated with atherosclerosis and mortality in most other diseases, in this group of patients, where hypertension occurs frequently either as the cause or the effect, the fall in blood pressure often denotes cardiac decompensation (28). Increased cTnT in this group of patients therefore indicates the presence of cardiac disease and hence, not surprisingly, the poorer outcome.

Both patients with sepsis affecting the myocardium had increased cTnT, consistent with previous studies showing it to be a prognostic marker in sepsis (18). Similar prognostic values in CHF patients have also been reported recently (15-17) and support our postulation that cTnT may be a useful prognosticator even in non-infarct-related cardiac disease. Such increases in cTnT may be indicative of non-infarct-related myocyte pathologies, as noted in our study.

With the use of serum troponins in acute coronary syndromes, there may be a need to reexamine the interpretation of the many risk-stratification studies of unstable angina and non-Q-wave MI patients (3-10). These studies used mainly cardiac end-points, and an increased mortality generally was attributed to underlying ischemic disease. In light of our findings, one should consider the presence of other myocardial pathologies, in addition to the presence of microinfarcts, as contributing factors for mortality. Interestingly, a study of patients with low-grade or atypical angina showed a greater than twofold difference in event-free survival at 6 months between cTnT-positive and -negative groups despite very similar incidences of positive angiographic abnormalities (64% vs 47%) (8). Increased troponins, especially cTnT, even in the absence of acute ischemia are indicative of compromised myocardium and carry a poor prognosis.

This study had several limitations. The nature of the study was such that samples could not be obtained from patients at a standard time before death. There also is the issue of the quality of the samples, both plasma and histologic. Because of the retrospective nature of the study, the plasma samples used were those that had been stored following routine analysis. Most of the samples were frozen within the recommended 72 h for the cTnI assay (29), and only 42% were frozen within the 24 h recommended for the cTnT assay (30). The effect, if significant, would have produced even greater discrepancy between the two troponins. In addition, recent studies have shown that degradation of cTnI complexes, which is the predominant form in serum, and oxidation or phosphorylation of the cTnI molecule can produce changes in immunoreactivity, leading to increasing or decreasing concentrations with storage (31). However, because only two patients with MI and one patient with sepsis were cTnT positive and cTnI negative, we do not think this had a major impact on our findings. Another limitation was that postmortem samples almost invariably show some autolysis, and more detailed studies, such as electron microscopy, were not possible. However, it would be ethically unacceptable at present to perform endomyocardial biopsies in patients to clarify the basis for increased serum troponins.

As data accumulate from clinical and laboratory studies, we need to reexamine the basis of increased troponins, especially cTnT, in patients without acute ischemia. The debate continues as to which troponin is superior. An important part of this debate is the poor specificity of cTnT in end-stage renal disease patients. Our findings imply that these increases, rather than being spurious, are indicative of underlying cardiac pathology. Although cTnI and cTnT are equal in the management of patients with acute coronary syndromes, cTnT is superior in detecting minimal cardiac disease and may be a better predictor of risk in certain groups of patients.

We thank Dr. G.A. Wells, Chairman and Professor, Department of Epidemiology and Community Medicine, University of Ottawa, for advice on statistical analyses.

Received August 31, 1999; accepted December 13, 1999.


(1.) Mair J, Artner-Dworzak E, Lechleitner P, Smidt J, Wagner I, Dienstl F, Puschendorf BL. Cardiac troponin T in diagnosis of acute myocardial infarction. Clin Chem 1991;37:845-52.

(2.) D'Costa M, Fleming E, Patterson MC. Cardiac troponin I for the diagnosis of acute myocardial infarction in the emergency department. Am J Clin Pathol 1997;108:550-5.

(3.) Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.

(4.) Lindahl B, Venge P, Wallentin L, for the FRISC Study Group. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation 1996;93: 1651-7.

(5.) Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.

(6.) Christenson RH, Duh S-H, Newby K, Ohman EM, Califf RM, Granger CB, et al., for the GUSTO-IIa Investigators. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. Clin Chem 1998;44: 494-501.

(7.) Holmvang L, Luscher MS, Clemmensen P, Thygesen K, Grande P, the TRIM Study Group. Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy). Circulation 1998;98:2004-9.

(8.) Mockel M, Stork T, Heller G Jr, Rocker L, Danne O, Darrelmann KG, et al. Troponin T in patients with low grade or atypical angina. Identification of a high risk group for short- and long-term cardiovascular events. Eur Heart J 1998;19:1802-7.

(9.) Galvani M, Ottani F, Ferrini D, Ladenson JH, Destro A, Baccos D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997;95:2053-9.

(10.) Solymoss BC, Bourassa MG, Wesolowska E, Dryda I, Theroux P, Mondor L, et al. The role of cardiac troponin T and other new biochemical markers in evaluation and risk stratification of patients with acute chest pain syndromes. Clin Cardiol 1997;20: 934-42.

(11.) Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. Clin Chem 1998;44:1410-6.

(12.) Frankel WL, Herold DA, Ziegler TW, Fitzgerald RL. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996;106:118-23.

(13.) McLaurin MD, Apple FS, Voss EM, Herzog CA, Sharkey SW. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. Clin Chem 1997;43:976-82.

(14.) Ooi DS, Veinot JP, Wells GA, House AA. Increased mortality in hemodialyzed patients with elevated serum troponin T--a one year outcomes study. Clin Biochem 1999;32:647-52.

(15.) Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with congestive heart failure. Am J Cardiol 1999;84: 608-11.

(16.) Collinson PO, Rao ACR, Naeem N, Gaze DG, Stubbs PJ, Mahon N, et al. Prognostic risk assessment in patients with severe congestive cardiac failure by cardiac troponin T measurement [Abstract]. Clin Chem 1999;45:A135.

(17.) Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J 1999;138:95-9.

(18.) Spies C, Haude V, Fitzner R, Schroder K, Overbeck M, Runkel N, Schaffartzik WL. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998;113:1055-63.

(19.) Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902-12.

(20.) Bertinchant J-P, Larue C, Pernel I, Ledermann B, Fabbro-Peray P, Beck L, et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem 1996;29:587-94.

(21.) Katus HA, Remppis A, Scheffold T, Diederich KW, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991;67:1360-7.

(22.) Adams JE III, Schechtman KB, Landt Y, Ladenson JH, Jaffe AS. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994; 40:1291-5.

(23.) Wu AHB, Feng Y-J, Moore R, Apple FS, McPherson PH, Buechler KF, Bodor GB, for the AACC subcommittee on cTnI standardization. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. Clin Chem 1998;44:1198-208.

(24.) Veinot JP, Gattinger DA, Fliss H. Early apoptosis in human myocardial infarcts. Hum Pathol 1997;28:485-92.

(25.) Sabbah HN, Sharov VG. Apoptosis in heart failure. Prog Cardiovasc Dis 1998;40:549-62.

(26.) Lowbeer C, Ottosson-Seeberger A, Gustafsson SA, Norrman R, Hulting J, Gutierrez A. Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. Nephrol Dial Transplant 1999;14:1948-55.

(27.) Roppolo LP, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at Veteran's Hospital: a pilot study. J Am Coll Cardiol 1999;34:448-54.

(28.) Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-85.

(29.) Abbott Laboratories. Abbott AxSYM[R] system Troponin-I. Technical insert. Abbott Park, IL: Abbott Laboratories, December 1997.

(30.) Roche Diagnostics. Elecsys[R] 1010/2010 systems Troponin T STAT immunoassay. Technical insert. Indianapolis, IN: Roche Diagnostics, January 1999.

(31.) Shi QM, Ling MF, Zhang XC, Zhang MY, Kadijevic L, Liu S, Laurino JP. Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays. Clin Chem 1999;45: 1018-25.

[4] Nonstandard abbreviations: CK-MB, creatine kinase-MB isoenzyme; MI, myocardial infarction; cTnT and cTnT, cardiac troponin I and T; and CHF, congestive heart failure.


Divisions of [1] Biochemistry and [2] Anatomical Pathology, Department of Pathology and Laboratory Medicine, Ottawa Hospital-Civic Campus, and [3] Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON Canada.

* Address correspondence to this author at: Division of Biochemistry, Department of Pathology and Laboratory Medicine, Ottawa Hospital-Civic Campus, 1053 Carling Ave., Ottawa, ON KlY 4E9 Canada. Fax 613-761-5401; e-mail
Table 1. Summary of patient and sample characteristics and pattern
of increased serum markers in the 66 patients (a) with
all four marker results available.

 DM (b)
 Males, and/or
 n % CRF, %

No myocardial pathologies 14 36 50
Old MI or fibrosis 7 43 29
Recent MI 11 82 18
Recent microinfarct 10 70 40
Healing MI 6 67 50
CHF 10 40 20
Other myocardial pathologies (d) 8 50 50

 Sampled Stored
 >6 days at 4[degrees]C
 prior to >72 h,
 death, % %

No myocardial pathologies 14 29
Old MI or fibrosis 29 0
Recent MI 27 36
Recent microinfarct 40 10
Healing MI 33 17
CHF 40 20
Other myocardial pathologies (d) 38 25

 No. (%) of patients with
 increased serum concentrations

 CK (c) cTnT

No myocardial pathologies 3 (21) 0
Old MI or fibrosis 2 (29) 0
Recent MI 2 (18) 2 (18)
Recent microinfarct 2 (20) 2 (20)
Healing MI 2 (33) 1 (17)
CHF 4 (40) 1 (10)
Other myocardial pathologies (d) 1 (13) 2 (25)

 No. (%) of patients with
 increased serum concentrations

 and cTnI cTnT
 cTnT only only

No myocardial pathologies 0 0 0
Old MI or fibrosis 0 1 (14) 1 (14)
Recent MI 2 (18) 0 2 (18)
Recent microinfarct 4 (40) 0 2 (20)
Healing MI 2 (33) 0 0
CHF 1 (10) 0 1 (10)
Other myocardial pathologies (d) 0 0 3 (38)

(a) Detailed information on all patients, including significant
medical history and cardiac findings at post mortem, is available
as a supplement from the Clinical Chemistry Web site. The file can be
accessed by a link from the on-line Table of Contents

(b) DM, diabetes mellitus; CRF, chronic renal failure.

(c) Increase in CK occurred in isolation or in combination with
another pattern group.

(d) Includes inflammation, necrosis, nonbacterial thrombotic
endocarditis, and amyloid deposition.

Table 2. Median and range of serum concentrations in the five
histologic groups, odds ratios of having abnormal pathology
compared with no myocardial pathology, and the significance based
on XZ analysis.

 No Old MI
 myocardial or patchy
 pathology fibrosis
 n 15 7
 Median, U/L 55 73
 Range, U/L 9-270 22-1085
 Odds ratio 1.0 1.60
 95% Cl (a) 0.1-18.8
 n 14 7
 Median, [micro]g/L 1.2 2.70
 Range, [micro]g/L 0.5-4.0 0.0-5.3
 Odds ratio 1.0 Undefined
 95% CI
 n 14 7
 Median, [micro]g/L 0.1 0.30
 Range, [micro]g/L 0.0-2.9 0.1-2.9
 Odds ratio 1.0 6.7
 95% CI 0.2-187.4
 n 15 9
 Median, [micro]g/L 0.02 0.03
 Range, [micro]g/L 0.00-0.07 0.01-0.15
 Odds ratio 1.0 10.30
 95% CI 0.4-243.5

 Recent/ myocardial
 healing MI CHF pathologies

 n 27 10 8
 Median, U/L 49 82 47
 Range, U/L 10-478 10-304 23-421
 Odds ratio 1.1 2.70 0.60
 95% Cl (a) 0.2-8.3 0.3-23.7 0.0-9.1
 n 27 10 8
 Median, [micro]g/L 2.5 3.10 2.20
 Range, [micro]g/L 0.9-75.7 0.9-15.9 1.0-18.4
 Odds ratio 3.2 4.60 11.20
 95% CI 0.1-72.1 0.2-124.7 0.5-266.9
 n 27 10 8
 Median, [micro]g/L 1.3 0.30 0.30
 Range, [micro]g/L 0.0-139.2 0.0-4.4 0.0-12.7
 Odds ratio 27.0 (b) 8.5 11.2
 95% CI 1.5-498.5 0.4-199.6 0.5-266.9
 n 34 12 8
 Median, [micro]g/L 0.13 0.07 0.26
 Range, [micro]g/L 0.00-13.11 0.0-1.41 0.03-0.62
 Odds ratio 49.4 (b) 22.7 (b) 48.7 (b)
 95% CI 2.7-895.4 1.1-467.8 2.2-1102.7

(a) CI, confidence interval.

(b) Significance based on [chi square] analysis: P <0.01 for
two-tailed test.

Fig. 1. Distribution of serum CK, CK-MB (MB), cTnI, and cTnT
concentrations in the various groups.

 CK MB cTnI cTnT

No myocardial 20% 0% 0% 0%

Old MI or 29% 0% 14% 22%
patchy fibrosis

Recent MI 19% 19% 48% 67%

Healing MI 33% 17% 50% 43%

CHF 40% 10% 20% 42%

Other cardiac 13% 25% 25% 63%

Filled portions of the columns and percentages shown above the
columns represent concentrations above the upper cutoff; gray
portions represent marginal increases (values between cutoff
and one-half the cutoff value); open portions represent no
significant increases (below one-half the cutoff value).

Note: Table made from bar graph.
COPYRIGHT 2000 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Enzymes and Protein Markers
Author:Ooi, Daylily S.; Isotalo, Phillip A.; Veinot, John P.
Publication:Clinical Chemistry
Date:Mar 1, 2000
Previous Article:Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum.
Next Article:Development of a new assay for complex I of the respiratory chain.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters